Zobrazeno 1 - 10
of 470
pro vyhledávání: '"William R Sellers"'
Autor:
Hasmik Keshishian, E Robert McDonald III, Filip Mundt, Randy Melanson, Karsten Krug, Dale A Porter, Luke Wallace, Dominique Forestier, Bokang Rabasha, Sara E Marlow, Judit Jane‐Valbuena, Ellen Todres, Harrison Specht, Margaret Lea Robinson, Pierre M Jean Beltran, Ozgun Babur, Meagan E Olive, Javad Golji, Eric Kuhn, Michael Burgess, Melanie A MacMullan, Tomas Rejtar, Karen Wang, DR Mani, Shankha Satpathy, Michael A Gillette, William R Sellers, Steven A Carr
Publikováno v:
Molecular Systems Biology, Vol 17, Iss 9, Pp n/a-n/a (2021)
Abstract Reliable methods to quantify dynamic signaling changes across diverse pathways are needed to better understand the effects of disease and drug treatment in cells and tissues but are presently lacking. Here, we present SigPath, a targeted mas
Externí odkaz:
https://doaj.org/article/8c21ac714ff142d89c9c58dde8847a35
Autor:
Hui Qin Wang, Ensar Halilovic, Xiaoyan Li, Jinsheng Liang, Yichen Cao, Daniel P Rakiec, David A Ruddy, Sebastien Jeay, Jens U Wuerthner, Noelito Timple, Shailaja Kasibhatla, Nanxin Li, Juliet A Williams, William R Sellers, Alan Huang, Fang Li
Publikováno v:
eLife, Vol 6 (2017)
The efficacy of ALK inhibitors in patients with ALK-mutant neuroblastoma is limited, highlighting the need to improve their effectiveness in these patients. To this end, we sought to develop a combination strategy to enhance the antitumor activity of
Externí odkaz:
https://doaj.org/article/4afc76bdbebd4dae8f0a7ad9feb5ec1d
Autor:
Sébastien Jeay, Swann Gaulis, Stéphane Ferretti, Hans Bitter, Moriko Ito, Thérèse Valat, Masato Murakami, Stephan Ruetz, Daniel A Guthy, Caroline Rynn, Michael R Jensen, Marion Wiesmann, Joerg Kallen, Pascal Furet, François Gessier, Philipp Holzer, Keiichi Masuya, Jens Würthner, Ensar Halilovic, Francesco Hofmann, William R Sellers, Diana Graus Porta
Publikováno v:
eLife, Vol 5 (2016)
Externí odkaz:
https://doaj.org/article/29da49791cad4fb8895cef0bf7f76fea
Autor:
Zineb Mounir, Joshua M Korn, Thomas Westerling, Fallon Lin, Christina A Kirby, Markus Schirle, Gregg McAllister, Greg Hoffman, Nadire Ramadan, Anke Hartung, Yan Feng, David Randal Kipp, Christopher Quinn, Michelle Fodor, Jason Baird, Marie Schoumacher, Ronald Meyer, James Deeds, Gilles Buchwalter, Travis Stams, Nicholas Keen, William R Sellers, Myles Brown, Raymond A Pagliarini
Publikováno v:
eLife, Vol 5 (2016)
The TMPRSS2:ERG gene fusion is common in androgen receptor (AR) positive prostate cancers, yet its function remains poorly understood. From a screen for functionally relevant ERG interactors, we identify the arginine methyltransferase PRMT5. ERG recr
Externí odkaz:
https://doaj.org/article/c4fb9b17bde6451983fdc615d4bf193b
Autor:
Anupama Reddy, Joseph D Growney, Nick S Wilson, Caroline M Emery, Jennifer A Johnson, Rebecca Ward, Kelli A Monaco, Joshua Korn, John E Monahan, Mark D Stump, Felipa A Mapa, Christopher J Wilson, Janine Steiger, Jebediah Ledell, Richard J Rickles, Vic E Myer, Seth A Ettenberg, Robert Schlegel, William R Sellers, Heather A Huet, Joseph Lehár
Publikováno v:
PLoS ONE, Vol 11, Iss 1, p e0146635 (2016)
Externí odkaz:
https://doaj.org/article/59c3f93f2d5c4482aef340a64a791f66
Autor:
Sébastien Jeay, Swann Gaulis, Stéphane Ferretti, Hans Bitter, Moriko Ito, Thérèse Valat, Masato Murakami, Stephan Ruetz, Daniel A Guthy, Caroline Rynn, Michael R Jensen, Marion Wiesmann, Joerg Kallen, Pascal Furet, François Gessier, Philipp Holzer, Keiichi Masuya, Jens Würthner, Ensar Halilovic, Francesco Hofmann, William R Sellers, Diana Graus Porta
Publikováno v:
eLife, Vol 4 (2015)
Biomarkers for patient selection are essential for the successful and rapid development of emerging targeted anti-cancer therapeutics. In this study, we report the discovery of a novel patient selection strategy for the p53–HDM2 inhibitor NVP-CGM09
Externí odkaz:
https://doaj.org/article/c47da66860c643148939459e36ed4a7e
Autor:
Anupama Reddy, Joseph D Growney, Nick S Wilson, Caroline M Emery, Jennifer A Johnson, Rebecca Ward, Kelli A Monaco, Joshua Korn, John E Monahan, Mark D Stump, Felipa A Mapa, Christopher J Wilson, Janine Steiger, Jebediah Ledell, Richard J Rickles, Vic E Myer, Seth A Ettenberg, Robert Schlegel, William R Sellers, Heather A Huet, Joseph Lehár
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0138486 (2015)
Death Receptor 5 (DR5) agonists demonstrate anti-tumor activity in preclinical models but have yet to demonstrate robust clinical responses. A key limitation may be the lack of patient selection strategies to identify those most likely to respond to
Externí odkaz:
https://doaj.org/article/65b59ba5d911495fa33f7b9acb527174
Autor:
Chrysiis Michaloglou, Waltraut Lehmann, Typhaine Martin, Clara Delaunay, Andreas Hueber, Louise Barys, Honglin Niu, Eric Billy, Markus Wartmann, Moriko Ito, Christopher J Wilson, Mary Ellen Digan, Andreas Bauer, Hans Voshol, Gerhard Christofori, William R Sellers, Francesco Hofmann, Tobias Schmelzle
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e61916 (2013)
The Hippo (Hpo) pathway is a novel signaling pathway that controls organ size in Drosophila and mammals and is deregulated in a variety of human cancers. It consists of a set of kinases that, through a number of phosphorylation events, inactivate YAP
Externí odkaz:
https://doaj.org/article/6648f287df874bcc8e7cfe07718ceb1a
Autor:
Simon Wöhrle, Andreas Weiss, Moriko Ito, Audrey Kauffmann, Masato Murakami, Zainab Jagani, Anne Thuery, Beatrice Bauer-Probst, Flavia Reimann, Christelle Stamm, Astrid Pornon, Vincent Romanet, Vito Guagnano, Thomas Brümmendorf, William R Sellers, Francesco Hofmann, Charles W M Roberts, Diana Graus Porta
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e77652 (2013)
Malignant rhabdoid tumors (MRTs) are aggressive pediatric cancers arising in brain, kidney and soft tissues, which are characterized by loss of the tumor suppressor SNF5/SMARCB1. MRTs are poorly responsive to chemotherapy and thus a high unmet clinic
Externí odkaz:
https://doaj.org/article/5ddabf7e37d840fe9ce647ad449900b5
Autor:
Irmgard Hofmann, Andreas Weiss, Gaelle Elain, Maria Schwaederle, Dario Sterker, Vincent Romanet, Tobias Schmelzle, Albert Lai, Saskia M Brachmann, Mohamed Bentires-Alj, Thomas M Roberts, William R Sellers, Francesco Hofmann, Sauveur-Michel Maira
Publikováno v:
PLoS ONE, Vol 7, Iss 8, p e44146 (2012)
Activating K-RAS mutations occur at a frequency of 90% in pancreatic cancer, and to date no therapies exist targeting this oncogene. K-RAS signals via downstream effector pathways such as the MAPK and the PI3K signaling pathways, and much effort has
Externí odkaz:
https://doaj.org/article/42b844c37e6f4ea7a9239610c2270b0d